Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292432133> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4292432133 endingPage "1162" @default.
- W4292432133 startingPage "1153" @default.
- W4292432133 abstract "Abstract Background and Objectives To evaluate the efficacy, safety and pharmacokinetics of a new, highly purified 10% IVIg (BT595, Yimmugo®) administered in children and adults with Primary immunodeficiency diseases (PID). Materials and Methods Prospective, uncontrolled, multicentre Phase III trial. Patients aged 2 to <76 years with PID were switched from their pre‐trial IVIg replacement therapy to BT595. In all, 67 patients (49 adults, 18 children) received doses between 0.2 and 0.8 g/kg body weight for approximately 12 months at intervals of 3 or 4 weeks. Dosing and dosing intervals were based on each patient's pre‐trial infusion schedule. The primary end point was the rate of acute serious bacterial infections (SBIs); secondary efficacy, safety and pharmacokinetic outcomes were also evaluated. Results The primary efficacy end point was met, and the unadjusted SBI rate was 0.01 per subject‐year (adjusted SBI rate 0.015 per subject‐year, with an upper limit of the one‐sided 99% confidence interval of 0.151). A single adult patient experienced one event classified as an SBI. All secondary end points, including those related to infections, supported the efficacy. Infusion rates were increased up to 8 ml/kg/h. Overall, 8% of infusions were associated with ≥1 infusional adverse event (AE) (start during or within 72 h post‐infusion), comprising mainly headache (2.4%), fatigue (0.9%) and nausea (0.5%). There were no infusional AEs at infusion rates of >4.0 ml/kg/h, and only one patient required a single premedication. The observed patterns, severity and frequency of treatment‐emergent adverse events are consistent with the established safety profile for IVIgs and did not show clinically relevant differences between all age groups. Conclusion BT595 is effective, safe and well tolerated for treating patients with PID." @default.
- W4292432133 created "2022-08-20" @default.
- W4292432133 creator A5016586425 @default.
- W4292432133 creator A5033886272 @default.
- W4292432133 creator A5050816060 @default.
- W4292432133 creator A5051303107 @default.
- W4292432133 creator A5059929801 @default.
- W4292432133 creator A5087817585 @default.
- W4292432133 creator A5090720454 @default.
- W4292432133 date "2022-08-09" @default.
- W4292432133 modified "2023-10-18" @default.
- W4292432133 title "Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease" @default.
- W4292432133 cites W1549201848 @default.
- W4292432133 cites W1862461292 @default.
- W4292432133 cites W1896431567 @default.
- W4292432133 cites W2071682030 @default.
- W4292432133 cites W2075175074 @default.
- W4292432133 cites W2088392367 @default.
- W4292432133 cites W2094655231 @default.
- W4292432133 cites W2125520756 @default.
- W4292432133 cites W2279672260 @default.
- W4292432133 cites W2465473010 @default.
- W4292432133 cites W2572233504 @default.
- W4292432133 cites W2734391405 @default.
- W4292432133 cites W2740879602 @default.
- W4292432133 cites W2794047672 @default.
- W4292432133 doi "https://doi.org/10.1111/vox.13337" @default.
- W4292432133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35944615" @default.
- W4292432133 hasPublicationYear "2022" @default.
- W4292432133 type Work @default.
- W4292432133 citedByCount "3" @default.
- W4292432133 countsByYear W42924321332022 @default.
- W4292432133 countsByYear W42924321332023 @default.
- W4292432133 crossrefType "journal-article" @default.
- W4292432133 hasAuthorship W4292432133A5016586425 @default.
- W4292432133 hasAuthorship W4292432133A5033886272 @default.
- W4292432133 hasAuthorship W4292432133A5050816060 @default.
- W4292432133 hasAuthorship W4292432133A5051303107 @default.
- W4292432133 hasAuthorship W4292432133A5059929801 @default.
- W4292432133 hasAuthorship W4292432133A5087817585 @default.
- W4292432133 hasAuthorship W4292432133A5090720454 @default.
- W4292432133 hasBestOaLocation W42924321331 @default.
- W4292432133 hasConcept C112705442 @default.
- W4292432133 hasConcept C126322002 @default.
- W4292432133 hasConcept C187212893 @default.
- W4292432133 hasConcept C188816634 @default.
- W4292432133 hasConcept C197934379 @default.
- W4292432133 hasConcept C203092338 @default.
- W4292432133 hasConcept C2777288759 @default.
- W4292432133 hasConcept C2778300832 @default.
- W4292432133 hasConcept C2779019163 @default.
- W4292432133 hasConcept C2779134260 @default.
- W4292432133 hasConcept C2780580376 @default.
- W4292432133 hasConcept C2780852908 @default.
- W4292432133 hasConcept C42219234 @default.
- W4292432133 hasConcept C44249647 @default.
- W4292432133 hasConcept C535046627 @default.
- W4292432133 hasConcept C71924100 @default.
- W4292432133 hasConceptScore W4292432133C112705442 @default.
- W4292432133 hasConceptScore W4292432133C126322002 @default.
- W4292432133 hasConceptScore W4292432133C187212893 @default.
- W4292432133 hasConceptScore W4292432133C188816634 @default.
- W4292432133 hasConceptScore W4292432133C197934379 @default.
- W4292432133 hasConceptScore W4292432133C203092338 @default.
- W4292432133 hasConceptScore W4292432133C2777288759 @default.
- W4292432133 hasConceptScore W4292432133C2778300832 @default.
- W4292432133 hasConceptScore W4292432133C2779019163 @default.
- W4292432133 hasConceptScore W4292432133C2779134260 @default.
- W4292432133 hasConceptScore W4292432133C2780580376 @default.
- W4292432133 hasConceptScore W4292432133C2780852908 @default.
- W4292432133 hasConceptScore W4292432133C42219234 @default.
- W4292432133 hasConceptScore W4292432133C44249647 @default.
- W4292432133 hasConceptScore W4292432133C535046627 @default.
- W4292432133 hasConceptScore W4292432133C71924100 @default.
- W4292432133 hasIssue "10" @default.
- W4292432133 hasLocation W42924321331 @default.
- W4292432133 hasLocation W42924321332 @default.
- W4292432133 hasOpenAccess W4292432133 @default.
- W4292432133 hasPrimaryLocation W42924321331 @default.
- W4292432133 hasRelatedWork W1964830422 @default.
- W4292432133 hasRelatedWork W1973977319 @default.
- W4292432133 hasRelatedWork W2062853605 @default.
- W4292432133 hasRelatedWork W2349236515 @default.
- W4292432133 hasRelatedWork W2372024866 @default.
- W4292432133 hasRelatedWork W2413665470 @default.
- W4292432133 hasRelatedWork W2431564509 @default.
- W4292432133 hasRelatedWork W2491636352 @default.
- W4292432133 hasRelatedWork W3128218392 @default.
- W4292432133 hasRelatedWork W4320923492 @default.
- W4292432133 hasVolume "117" @default.
- W4292432133 isParatext "false" @default.
- W4292432133 isRetracted "false" @default.
- W4292432133 workType "article" @default.